Ligand Pharmaceuticals Inc(LGND) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:03 PM ET (Korea 10/31 05:03)
Full metrics table
| Index | RUT | P/E | 143.96 | EPS (ttm) | 2.24 | Insider Own | 2.42% | Shs Outstand | 19.9M | Perf Week | 6.33% |
| Market Cap | 6.43B | Forward P/E | 26.04 | EPS next Y | 30.17% | Insider Trans | -15.82% | Shs Float | 19.4M | Perf Month | 6.61% |
| Enterprise Value | 7.12B | PEG | 1.17 | EPS next Q | 2.87 | Inst Own | 114.64% | Short Float | 12.86% | Perf Quarter | 10.52% |
| Income | 0.05B | P/S | 25.35 | EPS this Y | 17.12% | Inst Trans | 8.72% | Short Ratio | 10.42 | Perf Half Y | 41.91% |
| Sales | 0.25B | P/B | 6.65 | EPS next 5Y | 22.18% | ROA | 2.77% | Short Interest | 2.50M | Perf YTD | 70.7% |
| Book/sh | 48.57 | P/C | 14.38 | EPS past 3/5Y | - | ROE | 5.38% | 52W High | -1.19% ($326.63) | Perf Year | 72.54% |
| Cash/sh | 22.44 | P/FCF | 48.93 | Sales past 3/5Y | 10.96% 7.54% | ROIC | 2.46% | 52W Low | 83.5% ($175.89) | Perf 3Y | 534.46% |
| Dividend Est. | - | EV/EBITDA | 52.95 | EPS Y/Y TTM | 8.35% | Gross Margin | 96.58% | Volatility(W/M) | 3.06% 3.52% | Perf 5Y | 242.72% |
| Dividend TTM | - | EV/Sales | 28.03 | Sales Y/Y TTM | 1.03% | Oper. Margin | 14.38% | ATR (14) | 10.46 | Perf 10Y | 426.05% |
| Dividend Ex-Date | 2010/7/2 | Quick Ratio | 30.96 | EPS Q/Q | -125.1% | Profit Margin | 20.27% | RSI (14) | 63.39 | Recom | 1.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 31.18 | Sales Q/Q | -31.8% | SMA20 | 5.71% ($305.32) | Beta | 1.2 | Target Price | $360.36 |
| Payout | - | Debt/Eq | 1.17 | Earnings | 2026/10/29 | SMA50 | 8.89% ($296.4) | Rel Volume | 1.43 | Prev Close | $317.33 |
| Employees | 47 | LT Debt/Eq | 1.17 | EPS/Sales Surpr. | 14.66% 2.26% | SMA200 | 27.74% ($252.66) | Avg Volume(3M) | 0.24M | Price | $322.75 |
| IPO | 1992/11/18 | Option/Short | Yes/Yes | Trades | 7909 | Volume | 344,366 | Change | 1.71% |
💊 A biopharmaceutical royalty company built on a pharmaceutical royalty and formulation technology platform. Rather than selling its own drugs directly, its core model is an asset-light approach that provides technology and capital to other pharmaceutical companies for their new drug development and commercialization, in return for royalties. It holds multiple royalty assets along with formulation technology platforms such as Captisol.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded more than usual. That is 143% of its average volume.
LGND makes money exceptionally well
Of every $100 in sales, $14.38 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.1% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,604. Peers typically go for $2,474. It is about in line with its own 4-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +242.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 114.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #39 of 597 in the industry
Based on market cap of $6B.
LGND#39 Ligand Pharmaceuticals Inc $6B PER 144.0 
ORKA#40 Oruka Therapeutics Inc $6B PER - 
RYTM#41 Rhythm Pharmaceuticals Inc $6B PER - 
KOD#42 Kodiak Sciences Inc $6B PER - 
BLTE#43 Belite Bio Inc ADR $6B PER - 
FAQ
What kind of company is LGND?
LGND belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LGND?
The market cap of LGND is approximately $6.4B, ranking 1,182 within its sector.
What is the P/E ratio of LGND?
LGND has a P/E ratio of approximately 144.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LGND?
LGND has recorded a 52-week high of $326.63 and a low of $175.89.
